Episode 861: Theralase Technologies ($TLT.V | $TLTFF): A Novel Drug-and-Laser Approach to Bladder Cancer

This interview is disseminated on behalf of Theralase Technologies Inc.

Theralase Technologies (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger White provides an in-depth overview of the company’s light-activated small-molecule technology and its development for non-muscle-invasive bladder cancer.

Roger discusses the company’s completed clinical study enrollment, reported response and safety data, planned regulatory submissions to Health Canada and the FDA, and its collaboration with Ferring Pharmaceuticals.

Learn more: https://theralase.com/

Watch the full YouTube interview here: https://youtu.be/yeFJUx2w9d8
And follow us to stay updated: https://www.youtube.com/@stockstowatchofficial